METHODS: According to the random number generated by the block random method, 100 participants will be randomly and equally divided into the treatment group (YQD) or the control group (Ginkgo biloba extract tablets). The conversion rate of dementia will be used as the main evaluating indicator by the CDR scale. The MoCA scale, MMSE scale, ADCS-MCI-ADL-24 scale, CGIC-KDS scale, and 24-h ambulatory blood pressure will be used as the secondary evaluating indicator. Safety will be evaluated based on specific manifestations of adverse reactions and the incidence of adverse events.
OBJECTIVE: The objective is to estimate the curative effect of YQD (capsules) on hypertension in the elderly with MCI (deficiency of kidney essence syndrome), and to evaluate the safety of its clinical application.
BACKGROUND: Chinese Clinical Trial Registry (ICTRP member): ChiCTR2000030292.
方法:根据块随机方法生成的随机数,将100名参与者随机平均分为治疗组(YQD)或对照组(银杏叶提取物片)。CDR量表将以痴呆的转化率作为主要评价指标。MoCA量表,MMSE量表,ADCS-MCI-ADL-24量表,CGIC-KDS量表,24小时动态血压将作为次要评估指标。安全性将根据不良反应的具体表现和不良事件的发生率进行评估。
目的:目的是评价益气胶囊对老年高血压伴MCI(肾精不足证)患者的疗效。并评价其临床应用的安全性。
背景:中国临床试验注册中心(ICTRP成员):ChiCTR2000030292。